EN DE
Watch Immunocore Holdings Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Immunocore Holdings Ltd (IMCR) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Immunocore Holdings Ltd stock $24.50, price $28.88, that is 15.2% below the price, quality 40 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · Based in United Kingdom

IH Immunocore Holdings Ltd logo Thin data Nov 16, 2026

Immunocore Holdings Ltd

IMCR · US

Expensive (fair value 15% below the price), weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Ranks above peers (6/10) 
Last quarter vs. a year ago: revenue +18%, profit +150%. 
Quality 40/100 
Expensive Growth (revenue 5y +58.1 %/yr in USD) 
Moderate debt 
Fair value $24.50 · Overvalued 
Falling price (downtrend) 
Loss-making · -4.2% net margin (TTM) 
Negative free cash flow 
Narrow moat 13/100
Thin data 
Estimate
Watch Immunocore Holdings Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$75.36 $18.94 Fair Value $24.50 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

60‑month range $18.94 – $75.36 · fair‑value band $18.37 – $30.62 · the $28.88 price screens above the $24.50 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.

Follow Immunocore Holdings in your weekly email

Every Wednesday you see whether Immunocore Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally.

Show moreShow less

The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma.

It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME. In addition, the company is involved in the development of IMC-M113V which is in Phase 1 clinical trial for a potential functional cure of human immunodeficiency virus; and IMC-I109V which is in Phase 1 clinical trial for a potential functional cure of hepatitis B virus.

Further, it develops IMC-S118AI which is in pre-investigation stage for the treatment of type 1 diabetes; and IMC-U120AI which is in pre-investigation stage for the treatment of atopic dermatitis. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Stock analysis

Immunocore Holdings Ltd (IMCR) currently trades at $28.88, while our estimate is $24.50, 15% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $18.37 (bear) to $30.62 (bull), the price of $28.88 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Immunocore Holdings Ltd reported revenue of £298M in FY2025 versus £27.0M in FY2021, a compound +82.1%/yr. Reported net income was −£26.4M in FY2025.

Key figures

Market cap $1.5B Small · P/S ratio 3.70 · EPS (TTM) $−0.6400 · Net margin −8.9% · Return on equity −4.5% · Return on assets (EBIT) −11.3% (5-year average) · Operating margin −2.6% · Revenue (TTM) $431M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 13 out of 100 (medium confidence).

What moves the price

The share trades about 28% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −15%, IMCR screens richer than that median.

Fair Value

Bear $18.37 Fair Value $24.50 Bull $30.62
Price $28.88 · Downside -15.2%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 40/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 14
How much profit the company makes from its sales and capital
Quality Growth 73
Are margins and returns getting better?
Cashflow 4
Do the profits arrive as real cash?
Financial strength 51
Debt, balance sheet and risk of trouble
Investment 60
Does it invest with discipline instead of growing at any price?
Low Volatility 63
How calm the share price moves, does not count
Price momentum 27
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 11
Distance to the 52-week high, does not count
New shares 68
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

  • SaleBahija JallalCHIEF EXECUTIVE OFFICER, Director11,474 shares at $32.35$371,184Feb 18, 2026
  • SaleJohn GollSVP, FINANCE & CAO698 shares at $32.35$22,580Feb 18, 2026
  • SaleDavid M BermanHEAD OF R&D4× since Nov 24, 2025: 130,923 shares, avg. $39.79$5.2MFeb 18, 2026
  • SaleTina Amber St LegerCHIEF HR OFFICER1,000 shares at $32.35$32,350Feb 18, 2026

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+20.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+58.1%
Start year 2020 (pandemic). Over 10 years: +38.5% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+51.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−286.2% (2020) → −11.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

IMCR screens overvalued: fair value 15% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Immunocore Holdings Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks

Beats the industry median on 5/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 40 · Above median
Fair Value upside −15.2% · Above median
Profitability
Return on assets −2.5% · Above median
Net margin (12 months) −4.2% · Below median
Operating margin (12 months) −2.6% · Below median
Growth and dividend
Revenue growth (quarter YoY) 18.3% · Above median
Balance sheet
Debt / equity 1.03× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 3.90× · Pricier than median
P/S (12 months) 3.45× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)13 · sector 1
FUTURE (revenue growth)92 · sector 36
PAST (return on equity)0 · sector 0
HEALTH (low debt)48 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs IMCR
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs IMCR
Samsung Biologics Co 207940 1,414,000 KRW 1,552,100 KRW +10% vs IMCR
argenx SE ARGX $950.95 $908.40 −4% vs IMCR
CSL Limited CSL A$199.55 A$186.49 −7% vs IMCR
Moderna, Inc MRNA $215.27 $135.64 −37% vs IMCR
BeOne Medicines AG 6160 HK$247.40 HK$152.92 −38% vs IMCR
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs IMCR
Celltrion, Inc 068270 213,000 KRW 74,945 KRW −65% vs IMCR
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs IMCR

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Immunocore Holdings Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Immunocore Holdings Ltd Fair Value". https://www.fairvalue-calculator.com/stock/IMCR

Frequently asked questions

Is Immunocore Holdings Ltd (IMCR) overvalued or undervalued?
As of Nov 16, 2026, our estimate of fair value is $24.50 versus a price of $28.88, about 15% lower (overvalued).
What is the fair value of IMCR?
Our estimate for Immunocore Holdings Ltd is $24.50 (as of Nov 16, 2026), built from audited fundamentals. The current price: $28.88.
What is the quality score of IMCR?
Immunocore Holdings Ltd has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Immunocore Holdings Ltd (IMCR)?
Our calculated price target is the estimate of $24.50 (as of Nov 16, 2026). Cautious scenario $18.37, optimistic scenario $30.62. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Immunocore Holdings Ltd stock forecast for 2026?
Our estimate puts fair value at $24.50, about 15% lower versus a price of $28.88 (overvalued). Cautious scenario $18.37, optimistic scenario $30.62. The calculation is refreshed regularly with new filings.
What is the revenue of Immunocore Holdings Ltd (IMCR)?
Immunocore Holdings Ltd reported trailing-twelve-month revenue of about $431M (latest available figure, as of Nov 16, 2026).
What is the intrinsic value of Immunocore Holdings Ltd (IMCR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Immunocore Holdings Ltd it is $24.50 per share (as of Nov 16, 2026), against a price of $28.88.
Is Immunocore Holdings Ltd stock overvalued or undervalued in 2026?
As of Nov 16, 2026, IMCR trades above its calculated fair value: price $28.88, fair value $24.50, a gap of about −15% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IMCR?
No. The price is what the market pays today ($28.88); the fair value is what the company's own numbers justify ($24.50). For Immunocore Holdings Ltd the two are $4.38 per share apart. That gap is exactly why we show both numbers side by side.
How much is Immunocore Holdings Ltd worth?
The market values Immunocore Holdings Ltd at about $1.5B (market capitalisation, as of Nov 16, 2026). Per share that is $28.88; our models calculate a fair value of $24.50 per share.
What do the bullish and bearish scenarios say about IMCR?
Our models span a range for Immunocore Holdings Ltd: cautious scenario $18.37, base $24.50, optimistic $30.62 per share (as of Nov 16, 2026, price $28.88). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Immunocore Holdings Ltd (IMCR)?
Balance-sheet figures for Immunocore Holdings Ltd (as of Nov 16, 2026): return on equity −4.5%, debt of 1.03 per unit of equity. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is IMCR from its 52-week high?
Immunocore Holdings Ltd trades at $28.88, about 28% below its 52-week high of $40.22 and 4% above the low of $27.79 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of $24.50 is for.
Which stocks are comparable to Immunocore Holdings Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Immunocore Holdings Ltd stock attractive at the current price?
The data as of Nov 16, 2026: price $28.88, calculated fair value $24.50 (−15%), Quality Score 40/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Immunocore Holdings Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Immunocore Holdings Ltd (IMCR)?
The closing price on Nov 16, 2026 was $28.88. Our estimate is $24.50, about 15% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Immunocore Holdings Ltd right now?
Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Immunocore Holdings Ltd

How large is the market capitalisation of Immunocore Holdings Ltd (IMCR)?
The market capitalisation of Immunocore Holdings Ltd is $1.5B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Immunocore Holdings Ltd (IMCR)?
The price-to-sales ratio of Immunocore Holdings Ltd is 3.70 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Immunocore Holdings Ltd (IMCR)?
Earnings per share at Immunocore Holdings Ltd are $−0.6400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Immunocore Holdings Ltd (IMCR)?
The net margin of Immunocore Holdings Ltd is −8.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Immunocore Holdings Ltd (IMCR)?
The return on equity (ROE) of Immunocore Holdings Ltd is −4.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Immunocore Holdings Ltd (IMCR)?
On an EBIT basis the return on assets of Immunocore Holdings Ltd is −11.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Immunocore Holdings Ltd (IMCR)?
The operating margin of Immunocore Holdings Ltd is −2.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Immunocore Holdings Ltd (IMCR)?
Revenue at Immunocore Holdings Ltd is growing 18.3% versus a year earlier (3y avg +27.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Immunocore Holdings Ltd (IMCR)?
Earnings per share at Immunocore Holdings Ltd are growing 150% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Immunocore Holdings Ltd (IMCR) generate?
The free cash flow of Immunocore Holdings Ltd is −$11.2M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Immunocore Holdings Ltd (IMCR) hold?
Immunocore Holdings Ltd holds more cash than debt, $31.0M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Immunocore Holdings Ltd in the live analysis

One click puts Immunocore Holdings Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.